Characteristics and Outcomes of Pregnant Women Hospitalized With Laboratory-Confirmed Respiratory Syncytial Virus Before and During the COVID-19 Pandemic.

Autor: Milucky J; National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Patel K; National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Patton ME; National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA., Kirley PD; California Emerging Infections Program, Oakland, California, USA., Austin E; Colorado Department of Public Health and Environment, Denver, Colorado, USA., Meek J; Connecticut Emerging Infections Program, Yale School of Public Health, New Haven, Connecticut, USA., Anderson EJ; Departments of Medicine and Pediatrics, School of Medicine, Emory University, Atlanta, Georgia, USA.; Georgia Emerging Infections Program, Georgia Department of Public Health, Atlanta, Georgia, USA.; Atlanta Veterans Affairs Medical Center, Atlanta, Georgia, USA., Brooks A; Maryland Department of Health, Baltimore, Maryland, USA., Brown C; Michigan Department of Health and Human Services, Lansing, Michigan, USA., Mumm E; Minnesota Department of Health, St Paul, Minnesota, USA., Salazar-Sanchez Y; New Mexico Department of Health, Santa Fe, New Mexico, USA., Barney G; New York State Department of Health, Albany, New York, USA., Popham K; School of Medicine and Dentistry, University of Rochester, Rochester, New York, USA., Sutton M; Public Health Division, Oregon Health Authority, Portland, Oregon, USA., Talbot HK; Vanderbilt University Medical Center, Nashville, Tennessee, USA., Crossland MT; Salt Lake County Health Department, Salt Lake City, Utah, USA., Havers FP; National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Jazyk: angličtina
Zdroj: Open forum infectious diseases [Open Forum Infect Dis] 2024 Jan 31; Vol. 11 (3), pp. ofae042. Date of Electronic Publication: 2024 Jan 31 (Print Publication: 2024).
DOI: 10.1093/ofid/ofae042
Abstrakt: Background: Respiratory syncytial virus (RSV) can cause severe disease among infants and older adults. Less is known about RSV among pregnant women.
Methods: To analyze hospitalizations with laboratory-confirmed RSV among women aged 18 to 49 years, we used data from the RSV Hospitalization Surveillance Network (RSV-NET), a multistate population-based surveillance system. Specifically, we compared characteristics and outcomes among (1) pregnant and nonpregnant women during the pre-COVID-19 pandemic period (2014-2018), (2) pregnant women with respiratory symptoms during the prepandemic and pandemic periods (2021-2023), and (3) pregnant women with and without respiratory symptoms in the pandemic period. Using multivariable logistic regression, we examined whether pregnancy was a risk factor for severe outcomes (intensive care unit admission or in-hospital death) among women aged 18 to 49 years who were hospitalized with RSV prepandemic.
Results: Prepandemic, 387 women aged 18 to 49 years were hospitalized with RSV. Of those, 350 (90.4%) had respiratory symptoms, among whom 33 (9.4%) were pregnant. Five (15.2%) pregnant women and 74 (23.3%) nonpregnant women were admitted to the intensive care unit; no pregnant women and 5 (1.6%) nonpregnant women died. Among 279 hospitalized pregnant women, 41 were identified prepandemic and 238 during the pandemic: 80.5% and 35.3% had respiratory symptoms, respectively ( P < .001). Pregnant women were more likely to deliver during their RSV-associated hospitalization during the pandemic vs the prepandemic period (73.1% vs 43.9%, P < .001).
Conclusions: Few pregnant women had severe RSV disease, and pregnancy was not a risk factor for a severe outcome. More asymptomatic pregnant women were identified during the pandemic, likely due to changes in testing practices for RSV.
Competing Interests: Potential conflicts of interest. I. A., K. Y.-H., C. B., J. M., M. S., W. S., H. K. T., and M. H. report grants from the Centers for Disease Control and Prevention during the conduct of the study. E. A. reports personal fees from Pfizer, Sanofi Pasteur, GSK, Janssen, Moderna, and Medscape; grants from MedImmune, Regeneron, PaxVax, Pfizer, GSK, Merck, Sanofi Pasteur, Janssen, Moderna, and Micron; personal fees from Kentucky Bioprocessing, Sanofi Pasteur, WCG/ACI Clinical, and Moderna outside the submitted work. E. A.’s institution has also received funding from the National Institutes of Health to conduct clinical trials of COVID-19 vaccines. N. M. B. reports consulting agreement with GSK but has not performed or received compensation to date.
(Published by Oxford University Press on behalf of Infectious Diseases Society of America 2024.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje